

**Additional information under art. 33, par. 1, item 6
of Ordinance № 2 from 17 September 2003 of
"Sopharma" AD as at 30 September 2013**

1. Information about changes in accounting policies during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer – For the current financial period the Company has adopted all new and / or revised standards and interpretations issued by the International Accounting Standards Board (IASB), respectively. The Interpretations Committee of the IFRS, which are relevant to its operations. More detailed information about the Company's accounting policies can be found at 2.1. Basis of preparation of the financial statements for 2013 in the notes to the interim financial statement for the third quarter.

2. Information about changes in the economic group of the issuer, if participating in a group: No new subsidiaries have been acquired in the third quarter of 2013.

3. Information about the results of organizational changes within the issuer, such as restructuring, sale of companies from the group, in-kind contributions from companies, rental property, long-term investments, closure of business:

On 29 October 2012 was signed a merger agreement between Sopharma AD and Bulgarian Rose Sevtopolis AD, which settles the conduction of the transformation through merging of Bulgarian Rose Sevtopolis AD into Sopharma AD. The agreement along with the accompanying documentation has been submitted to the Financial Supervision Commission. By Decision №396 – PD from 23 May 2013 the Financial Supervision Commission did not approve the Contract for transformation through merging of Bulgarian Rose Sevtopolis AD in Sopharma AD.

The Company leased tangible fixed assets with carrying amount of 7,435 thousand BGN as at 30 September 2013 to related parties (31 December 2012: 7,811 thousand BGN). In addition, tangible fixed assets at carrying amount of 46 thousand BGN were leased to third parties as at 30 September 2013 (31 December 2012: 42 thousand BGN).

The book value of the investments in subsidiaries is as follows:

		30.09.2013	Interest	31.12.2012	Interest
		BGN '000	%	BGN '000	%
Sopharma Trading AD	Bulgaria	30 222	76.16	32 148	81.01
Unipharm AD	Bulgaria	19 448	49.99	19 449	49.99
Briz OOD	Latvia	8 768	51.01	6 262	51.00
Bulgarian Rose Sevtopolis AD	Bulgaria	8 729	49.99	8 729	49.99
Biopharm Engineering AD	Bulgaria	8 384	97.15	8 384	97.15
Vitamina AD	Ukraine	6 187	99.56	6 187	99.56
Ivanchich and sons	Serbia	5 739	51.00	5 739	51.00
Momina Krepost AD	Bulgaria	2 660	52.16	2 547	49.94
Pharmalogistica AD	Bulgaria	1 911	76.54	1 911	76.54
Sopharma Buildings REIT	Bulgaria	643	42.89	639	42.64
Electroncommerce EOOD	Bulgaria	384	100.00	384	100.00
Sopharma Warsaw EOOD	Poland	323	100.00	323	100.00
Sopharma Ukraine EOOD	Ukraine	230	100.00	230	100.00

93 628

92 932

As of 30 September 2013, the investments in the subsidiaries Sopharma Poland OOD - in liquidation, Poland, Extab Corporation, USA and Sopharma, USA are fully impaired (31 December 2012: fully impaired are Zdrovit Sopharma AD - in liquidation, Poland, Sopharma Poland OOD - in liquidation, Poland, Extab Corporation, USA and Sopharma USA). On 25 February 2013 completed the liquidation of Sopharma Zdrovit AD, Poland, and the company was erased from the National Court Register of Poland.

Sopharma has direct or indirect control over the above listed companies.

4. Opinion of the governing body regarding the feasibility of the published estimates of the results for the current financial year, taking into account the results of the current quarter as well as information on the factors and circumstances that will affect the achieving of the projected results for at least the next quarter - no update of the forecast results.

5. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter;

SHAREHOLDERS	Number of shares /%// 30 September 2013	Number of shares /%// 30 June 2013
„Donev Investment Holding” AD, EIK 831915121, Sofia, Positano Str. № 12	33 793 918 /25,60%/	34 029 223 /25,78%/
“Telecomplex Invest” AD, EIK 201653294, Sofia, Slaveikov Square № 9	26 948 052 /20,42%/	26 948 052 /20,42%/
„Finance Consulting Company” EOOD EIK 121414242 Sofia, Khan Krum Str. 10	0 /0%/	11 999 038 /9,09%/
„Rompharm Compnay” OOD UID 200732874 Sofia, Mladost residential complex, Boian Damianov Str. 7, office 3	17 859 454 /13,53%/	5781165 /4,38%/
Universal Pension Fund “Doverie” AD, EIK 130474628 Sofia, Dunav Str. 5	8 906 997 /6,75%/	8 906 997 /6,75%/

6. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter:

Members of the Board of Directors	Number of shares 30 September 2013	Number of shares 30 June 2013
1. Ognian Ivanov Donev	0	0
2. Vessela Liubenova Stoeva	0	0
3. Andrey Liudmilov Breshkov	0	0
4. Ognian Kirilov Palaveev	54320	54320
5. Alexander Viktorov Chaushev	87414	87414

7. Information on pending judicial, administrative or arbitration proceedings relating to liabilities or receivables amounting to at least 10 percent of the equity of the Company - none.

8. Information on loans granted by the issuer or their subsidiary, provided guarantees or commitments to a single person or a subsidiary thereof, including to related persons with indication of the nature of the relationship between the issuer and the person, the amount of the outstanding principal, the interest rate, the maturity, the size of commitment, the terms and conditions.

Loans granted to related parties by type of relationship:

	30.09.2013 BGN '000	31.12.2012 BGN '000
Companies under a common control through key managing personnel	49 408	37 156
Companies under common indirect control	7 739	13 078
<i>Impairment of commercial loans</i>	-	(2 358)
	<u>7 739</u>	<u>10 720</u>
Subsidiaries	6 997	6 408
Companies – main shareholders	-	8 170
Total	<u>64 144</u>	<u>62 454</u>

The terms of the loans granted to related parties are as follows:

Currency	Contracted amount '000	Maturity	Interest %	30.09.2013		31.12.2012	
				BGN'000	BGN'000 including interest	BGN'000	BGN'000 including interest
<i>to companies under common indirect control through key managing personnel</i>							
BGN	23 395	31.12.2013	8.30%	20 904	1 380	14 932	324
EUR	8 793	31.12.2013	4.50%	13 847	78	12 257	62
BGN	27 050	31.08.2013	8.08%	11 299	569	9 230	-
BGN	2 500	31.12.2013	8.30%	2 615	115	-	-
BGN	1 300	31.12.2013	8.08%	540	40	510	9
BGN	190	31.12.2013	8.08%	203	13	227	37
<i>to companies under common indirect control</i>							
EUR	7 660	31.12.2013	4.50%	7 739	39	10 010	-
BGN	1 375	31.12.2013	8.08%	-	-	710	-
<i>to companies – main shareholders</i>							
EUR	4 035	31.12.2013	4.80%	-	-	8 170	278
<i>to subsidiaries</i>							
EUR	2 770	20.01.2014	6.10%	6 309	892	6 062	645
BGN	600	31.12.2013	7.00%	302	2	101	-
USD	205	31.12.2013	3.50%	307	10	167	4
USD	25	31.12.2013	3.50%	40	3	40	2
USD	20	31.12.2013	3.50%	32	3	32	3
EUR	3	07.11.2013	13.00%	7	-	6	-
				64 144	3 144	62 454	1 364

As at 30 September 2013 there are pledges on receivables from related parties amounting to 16,229 thousand BGN (31 December 2012: 10,500 thousand BGN) (Note №26 and №29) as collateral for bank loans, received by the Company.

The terms and conditions of the loans granted to third parties are as follows:

Currency	Contracted amount '000	Maturity	Interest %	30.09.2013		31.12.2012	
				BGN'000	BGN'000 including interest	BGN'000	BGN'000 including interest
BGN	1 800	30.06.2014	6.80%	559	1	-	-
BGN	298	23.02.2014	7.00%	391	13	300	2
BGN	31	31.12.2013	6.00%	34	3	33	2
BGN	30	25.07.2014	8.08%	31	1	-	-
BGN	350	30.06.2014	6.80%	7	-	6	-
BGN	100	31.12.2013	8.08%	-	-	108	8
				1 022	18	447	12

Ognian Donev, PhD
Executive Director